Friedrich Schulze

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Chronic Kidney Disease

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Naunyn-Schmiedeberg's archives of pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Diane Wong, Friedeborg Seitz, Verena Bauer, Thomas Giessmann, Friedrich Schulze
Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials. Naunyn-Schmiedeberg's archives of pharmacology (2024)
Stefan R Bornstein, Dick de Zeeuw, Hiddo J Lambers Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine R Tuttle, Samy Hadjadj, Ellen Burgess
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial. Diabetes, obesity & metabolism (2024)
Stefan R Bornstein, Dick de Zeeuw, Hiddo J Lambers Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine R Tuttle, Samy Hadjadj, Ellen Burgess
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial. Diabetes, obesity & metabolism 26 (6) (2024)
Stefan R Bornstein, Dick de Zeeuw, Hiddo J Lambers Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine R Tuttle, Samy Hadjadj, Ellen Burgess
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial. Diabetes, obesity & metabolism 26 (6) (2024)